Cohance Lifesciences Limited — Investor Meet, 15-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Cohance Lifesciences reported FY26 revenue of INR 2,268 Cr (-13% YoY) with Adjusted EBITDA of INR 477 Cr (21% margin). Q1 FY27 is projected to be weak, marking a bottoming-out phase, with growth and recovery expected from H2 FY27. CDMO revenue (INR 889 Cr) saw underlying single-digit growth despite destocking, with 10 Phase 3 programs. API+ (INR 1,088 Cr) declined 8% due to product issues and Nacharam site disruption but improved in H2. Specialty Chemicals (INR 291.3 Cr) had a marginal decline. New CEO Umang Vohra highlighted strategic priorities: leveraging unique science (ADCs, oligos), operational rigor, and deepening customer ties. Sentiment is cautiously optimistic for a H2 turnaround.